STAT3 and hepatocellular carcinoma: Li Y. et al. (2018) showed that AS-IV (160 μg/mL) significantly downregulated the expression of lncRNA-ATB in HCC cells in a dose- and time-dependent manner. Further investigation revealed that overexpression of lncRNA-ATB could reverse the effects of AS-IV on HCC cell migration, EMT, apoptosis, cell viability and IL-11/STAT3 signaling pathway (Li Y. et al., 2018). These effects were likely due to the inhibition of lncRNA-ATB by AS-IV, which in turn suppressed HCC cell migration and viability (Li Y. et al., 2018).